Exact Sciences (EXAS) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for its previously announced license agreement with Freenome. Under the agreement, the company acquired exclusive rights in the United States to Freenome’s blood-based colorectal cancer screening tests. The exclusive license expands Exact Science’s leadership in cancer screening by adding blood-based CRC screening options to its portfolio. Exclusivity remains subject to Freenome’s test receiving first-line FDA approval.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target raised to $85 from $65 at Citi
- Cathie Wood Buys the Dip in Archer Aviation (ACHR) After Weak Q3 Results, Trims Stakes in Roku and TER Stocks
- Exact Sciences announces results from ALTUS study
- Exact Sciences Corp Faces Regulatory Risks Amid Potential Government Disruptions
- Exact Sciences Corp Reports Strong Q3 Earnings